MRK in “The Patent Cliff Sparks a Biotech Land Grab”
Merck & Co., Inc.
Merck must replace an exceptionally large Keytruda revenue base as its principal patents approach expiration.
MRK impact map — “The Patent Cliff Sparks a Biotech Land Grab”
How this story travels from the headline to MRK’s own business — positive, negative or mixed, direct or indirect, the mechanism, and how strong the exposure is.
Loading MRK impact map…
Price history, marked with story events
Oct 20, 2025 – Oct 19, 2026 · 252 sessions
Prices updated during market hours · refreshed about every 30 minutes while the market is open · delayed data, not for trading decisions
Numbered markers tie price moves to earnings, trial or study results, management comments and analyst or demand data. Loading events…
Full story
The Patent Cliff Sparks a Biotech Land Grab
Large drugmakers facing revenue holes must buy scarce pipelines, turning clinical validation into strategic currency.
BEAR side — Merck must replace an exceptionally large Keytruda revenue base as its principal patents approach expiration.
Read the full The Patent Cliff Sparks a Biotech Land Grab storyBull side
2 stories- GLP-1 Eats Everything
MRK in “GLP-1 Eats Everything”
FadingExposure: not rated yetAppetite suppression as a macro variable.
Merck's oral GLP-1 and broader cardiometabolic pipeline gives it a path to participate in the expanding obesity-drug market.
- China Becomes Pharma's Global R&D Engine
MRK in “China Becomes Pharma's Global R&D Engine”
FadingExposure: not rated yetWestern drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.
Merck can use China-sourced combinations and next-generation mechanisms to extend its oncology franchise beyond Keytruda.
Bear side
2 stories- America Imports the World's Drug Prices
MRK in “America Imports the World's Drug Prices”
StableExposure: not rated yetUS reference pricing puts global blockbuster economics—and not just American list prices—under pressure.
Reference pricing threatens the long-duration cash flows attached to Keytruda and Merck's next generation of patented medicines.
- Viewing
MRK in “The Patent Cliff Sparks a Biotech Land Grab”
FadingExposure: not rated yetLarge drugmakers facing revenue holes must buy scarce pipelines, turning clinical validation into strategic currency.
Merck must replace an exceptionally large Keytruda revenue base as its principal patents approach expiration.